|Articles|December 1, 2003

In young children, SARS may be mild and nonspecific

Bitnun A et al: Pediatrics 2003;112:e261

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

ARTEMIS trial data show Bifidobacterium-HMO synbiotic is safe and colonizes the infant, toddler gut | Image Credit: © Emiliia - stock.adobe.com.

ARTEMIS trial data show Bifidobacterium-HMO synbiotic is safe and colonizes the infant, toddler gut

ByMorgan Ebert, Executive Editor

September 8th 2026

A teenaged girl with flat-topped papules

Can you guess the diagnosis of this teenaged girl with flat-topped papules?

ByZeena Mestari,Bernard A Cohen, MD

September 8th 2026

Contemporary Pediatrics week in review: August 31-September 4, 2026

Contemporary Pediatrics week in review: August 31-September 4, 2026

ByContemporary Pediatrics Staff

September 7th 2026

What to expect in the August/September 2026 issue of Contemporary Pediatrics

ByTina Q. Tan, MD, FAAP, FIDSA, FPIDS

September 7th 2026

Abbott launches first ready-to-feed whole milk infant formula in the U.S. | Image credit: © Abbott

Abbott launches first ready-to-feed whole milk infant formula in the U.S.

ByMorgan Ebert, Executive Editor

September 7th 2026

Latest CME

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Trending on Contemporary Pediatrics

Abbott launches first ready-to-feed whole milk infant formula in the U.S.

FDA news in pediatrics: August 2026

Bifidobacteria Decline: Causes and Consequences for Infant Gut Health

The unharmonious 2026 child and adolescent immunization schedule

FDA approves zilganersen (Zanvastro) as first treatment for Alexander disease